Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$128.87+1.65%
Close 2026-07-07 · 1-day change
Reading MRK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRK free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading MRK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRK free→QuarterlyIQ Insights · MRK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 50% of the time over the next year (vs 42% for the rest of the cohort, n=9129).
Over the trailing year it converted 2.00x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 49% of the time over the next year (vs 41% for the rest of the cohort, n=3127).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 50% for the rest of the cohort, n=3552).
Not investment advice. As of 2026-07-07.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.